US EditionNovo Nordisk Shares Extend Losses, Erasing Nearly All Gains Since Wegovy Launch
10 Articles
10 Articles
Novo Nordisk shares extend losses, erasing nearly all gains since Wegovy launch
Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to wipe out almost all the gains made since the drugmaker launched its blockbuster weight-loss treatment Wegovy.
"Of course it's serious when Trump goes out and puts pressure like this."
Novo Nordisk shares were hit with a shocker this week. The company's shares took a cold shower, plunging more than 25 percent. Trading was even briefly suspended. While the company continues to post solid sales and profit growth, investors were surprised by a downgrade in its outlook that came outside of its scheduled earnings release, as well as the ongoing battle for market share in the weight loss drug space. This article is for subscribers o…
The darkest week in history in the Danish pharmaceutical listing closes with a new corrective. Donald Trump’s pressure today plunges Novo Nordisk’s quote to a minimum of four years. Read
Novo Nordisk's nightmare week began with a sharp reduction in the full-year forecast and the announcement of a new CEO. Trump's new demands fuel the decline on Friday.
The Danish pharmaceutical giant will receive new price blows at the stock exchange opening today.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
